Rebyota is a therapy manufactured by stool donations that are screened for dozens of infections and viruses. It is delivered via the rectum as a one-time procedure. Two studies showed 70 percent of people who received Rebyota overcame C. diff after eight weeks, compared to 58 percent of patients who received a placebo.
Fecal transplants have been shown to help recipients fight C. diff bacteria, and the treatment has grown more common as many patients no longer respond to antibiotics. However, regulating the fecal matter used has been a “regulatory headache for the FDA,” according to the report.
The treatment is only for patients who have already taken a course of antibiotics for recurrent infection.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.